HOOKIPA Pharma (HOOK) said late Wednesday that it would reduce its workforce by about 80% as part of its restructuring plan.
The company said it expects to begin the restructuring plan in Q4 and substantially complete it by the end of the first half of 2025.
As part of its restructuring plan, the company will pause clinical development of its eseba-vec program for HPV16-positive head and neck cancers, including the early termination of a phase 1/2 trial, despite no issues with efficacy or safety.
Additionally, Hookipa said it also prioritize its HB-700 program for KRAS mutant cancers, which received FDA clearance in April 2024.
The company will continue enrolling patients in its HB-500 HIV program and supporting its HB-400 Hepatitis B program, both developed in partnership with Gilead Sciences.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。